Aplastic Anemia

As a physician–scientist, Dr. Tibes is grateful for the opportunity to advance treatments for people who have cancer through my own groundbreaking research. He has been involved in developing national treatment guidelines for leukemia, and he has been actively engaged in translational research to identify and develop new leukemia treatments over the last few years. Many of these treatments, which directly target the DNA of cancer cells or push leukemia cells to die, were developed in Dr. Tibes' laboratory and have led to clinical trials and U.S. Food and Drug Administration approvals. In his

Tiffany N. Tanaka, MD, is a board-certified hematologist specializing in the diagnosis and treatment of blood cancers and blood disorders, with an emphasis on myeloid malignancies. Dr. Tanaka is a translational researcher who focuses on the development of early phase trials that offer new cancer treatments for patients. Her research work includes the study of epigenetic and genetic biomarkers in myelodysplastic syndromes (bone marrow disorders in which the bone marrow does not produce enough healthy blood cells), with the aim of translating these into clinical therapies to improve patient care

Dr. Tamari is a board-certified hematologist and oncologist specializing in the use of stem cell transplantation to treat patients with hematologic malignancies (cancers that arise from blood cells). She works as part of a multidisciplinary team of transplantation specialists who treat patients with these diseases. As a clinical researcher, Dr. Tamari's work focuses on identifying risk factors associated with relapse after allogeneic stem cell transplantation for myelodysplastic syndrome and acute muyelogenous leukemia. Together with her colleagues she is developing protocols for early post